Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Acadia Pharmaceuticals (ACAD)

Acadia Pharmaceuticals Q1 revenue up 19% to $244.3 million; guidance reiterated

Positive Impact 3 of 5 earnings Written later

Acadia Pharmaceuticals reported first quarter 2025 total revenues of $244.3 million, up 19% from a year earlier, and net income of $19.0 million, or $0.11 per diluted share, compared with $16.6 million, or $0.10 per share, in the first quarter of 2024. The company reiterated most of its full year 2025 guidance but raised its R&D expense range to $330 million to $350 million, citing the accelerated timing of the ACP-101 Phase 3 study.

Key points

  • Total revenues of $244.3 million, up 19%; NUPLAZID net product sales of $159.7 million, up 23%; DAYBUE net product sales of $84.6 million, up 11%
  • Net income of $19.0 million, or $0.11 per diluted share, versus $16.6 million, or $0.10 per share, a year earlier
  • Full year 2025 R&D expense guidance raised to $330 million to $350 million from $310 million to $330 million; other guidance reiterated
  • Cash, cash equivalents and investment securities of $681.6 million at March 31, 2025, down from $756.0 million at December 31, 2024, after $98.8 million in payments to Neuren

The filing

CompanyAcadia Pharmaceuticals (ACAD)
Form8-K, current report
Filed with the SECMay 7, 2025, 4:13 PM ET
Accession number0000950170-25-065672

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:38 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.